New heart Drug's secret powers revealed in small trial
NCT ID NCT05704478
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how vericiguat, a recently approved heart failure drug, improves heart function during activity and at rest. Researchers will give 30 adults with heart failure either vericiguat or a placebo for about three months, then measure heart performance using catheterization and exercise tests. The goal is to understand why the drug helps patients live longer and avoid hospital stays.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Colorado, Anschutz Medical Campus
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?